Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.

Type 1 diabetes mellitus results from autoimmune destruction of pancreatic β cells. Insulin treatment is often inadequate in preventing devastating complications. Replacing β cells using stem cell-derived islets while fostering immune tolerance, exemplified in Yoshihara et al., holds the promise of a curative therapy for this disease.
Competing Interests: Declaration of Interests J.A.B. is the A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology and a member of the Scientific Advisory Boards of Arcus Biosciences, Celsius Therapeutics, and VIR Biotechnology. J.A.B. is a member of the Board of Directors of Rheos Medicines and Provention Bio, a company actively involved in the development of Teplizumab and other T1D-directed therapies. J.A.B. is a co-founder, President, and CEO and Q.T. is a co-founder and advisor of Sonoma Biotherapeutics, a company involved in developing novel Treg-based cell therapies for the treatment of autoimmune diseases. J.A.B. and Q.T. hold stock and are compensated by Sonoma Biotherapeutics. J.A.B. holds stock and is compensated by Provention Bio, Arcus Biosciences, Celsius Therapeutics, Rheos Medicines, and VIR Biotechnology. Q.T. is an advisor of Encellin, eGenesis, and Qihan Bio.
(Copyright © 2020 Elsevier Inc. All rights reserved.)